Drugs / vYF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04942210 | Jul 2021 → Jun 2022 overdue | yellow fever | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vYF | “A next-generation, live-attenuated yellow fever vaccine, vYF, was developed in Vero cells to improve vaccine supply and availability.” PMID 41950474 ↗ Apr 2026 |
| Modality | Vaccine | “A next-generation, live-attenuated yellow fever vaccine, vYF” PMID 41950474 ↗ Apr 2026 |